Table 1 (abstract P24). NNT, NNH and LHH for CM and EM prophylactic treatments
| Â | Chronic migraine (CM) | Episodic migraine (EM) | |||||
|---|---|---|---|---|---|---|---|
Erenumab 140 mg | Topiramate 100 mg | Onabotulinum-toxin A | Erenumab 140 mg | Topiramate 100 mg | Propranolol 160 mg | ||
Data source : | NCT 02066415 | Silberstein et al 2007 & 2009 | Diener et al 2007 | Dodick et al 2010 | NCT 02456740 | Bussone et al 2005 | Diener et al 2004 |
NNT ≥50% RR (95%CI) | 6 (4,12) | 13 (NE, NE) | 4 (3, 10) | 9 (6, 15) | 6 (4, 9) | 5 (4, 6) | 5 (4, 10) |
NNH % d/c due to AEs (95%CI) | 250 (NE, NE) | 21 (NE, NE) | 13 (NE, NE) | 39 (23, 100) | 1000a (NE, NE) | 8 (6, 13) | 11 (6, 72) |
LHH NNH/NNT (95%CI) | 41.7 (5.3, 301.8) | 1.6 (0.0, 112.8) | 3.3 (0.7, 364.9) | 4.3 (1.9, 11.4) | 166.7 (9.0, 299.3) | 1.6 (1.1, 3.1) | 2.2 (0.8, 14.5) |